From: 2015 Update on Acute Adverse Reactions to Gadolinium based Contrast Agents in Cardiovascular MR. Large Multi-National and Multi-Ethnical Population Experience With 37788 Patients From the EuroCMR Registry
All
RS CAD
MYO/CMP
Viability
Severe
2/37788 (0,01%)
2/18840 (0,01%)
0/14106 (0%)
0/4037 (0%)
Mild
43/37788 (0,11%)
7/18840 (0,04%)
22/14106 (0,16%)
9/4037 (0,22%)
45/37788 (0,12%)
9/18840 (0,05%)